Close

Trillium Therapeutics (TRIL) Approved by FDA to Commence TTI-621 Phase 1 in olid Tumors and Mycosis Fungoides

August 17, 2016 7:06 AM EDT Send to a Friend
Trillium Therapeutics Inc. (Nasdaq: TRIL) announced that the US Food and Drug Administration (FDA) has provided the company clearance to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login